PO.ET08.02 · 实验与分子治疗
Radiopharmacuetical Platforms for Theranostic Precision Oncology
- 5807 5807 纳米抗体与特化连接子文库的协同整合：一种新型放射性核素药物偶联物（RDC）平台，为具有最佳成药性和治疗指数的下一代放射治疗药物铺平道路 Synergistic integration of nanobodies and a specialized linker library: A novel radionuclide drug conjugate (RDC) platform paving the way for next-generation radiotherapeutics with optimal druggability and therapeutic index Chong Liu, Zengyan Mu, Sipeng Li, Qingsong Wu, Yajun Sun, Paul H. Song, Gang Qin
- 5810 5810 [212Pb]Pb-AG1206：一种新型成纤维细胞活化蛋白靶向放射性配体疗法，展现出卓越的疗效和安全性 [ 212 Pb]Pb-AG1206, A novel fibroblast activation protein-targeted radioligand therapy demonstrated excellent efficacy and safety profile Xin Gan, Tao Robert Wu, Miaomiao Song, Shaohua Xu, Guiyu Liu, Vivi Yang, Jinpeng Liu, Xuefei Li, Hu Li, Zhen Cheng, Maijing Liao
-
- 5812 5812 [177Lu]Lu-PSMA-617和[225Ac]Ac-PSMA-617在荷去势抵抗性前列腺腺癌患者源性异种移植瘤小鼠中的临床前评估 Preclinical evaluation of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in mice bearing castration-resistant prostate adenocarcinoma patient-derived xenografts Denis Beckford-Vera, Jaeho Lee, Kyle Monger, Erin Kosmowski, Kayla Cotton, Sebastian Brabetz, Markus Hippich, Sarah Maenhout, Paul Heverly, Maria Mancini
-
-
-
-
- 5817 5817 一种新型NTSR1靶向α放射治疗药物SKL35501在HCT116结直肠肿瘤模型中展现出强效抗肿瘤疗效 A novel NTSR1-targeting alpha radiotherapeutic SKL35501 demonstrating potent anti-tumor efficacy in HCT116 colorectal tumor model Jungtae Na, Taeyun Lee, Seona Jeon, Hyunseok Lee, Sunghak Lee, Sungwan Hwang, Jungshin Park
-
- 5819 5819 PD-L1靶向放射治疗可在三阴性乳腺癌小鼠模型中减少肿瘤负荷并延缓肿瘤生长 PD-L1 targeted radiotherapy can reduce tumor burden and delay tumor growth in a mouse model of triple-negative breast cancer Jonathan Moye, Hailey Houson, Sharmila Sridhar, Sherin James, Jason M. Warram, Suzanne E. Lapi, Anna G. Sorace
- 5820 5820 使用Alpha-SPECT Mini和伽马计数对乳腺、前列腺和胶质母细胞瘤模型中镥-177放射性药物的生物分布分析 Biodistribution analysis of Leutetium-177 radiopharmaceuticals in mammary, prostate, and glioblastoma models using Alpha-SPECT Mini and gamma counts Kathryn R. Meshaw, William F. Durham, Karsten E. Fynboe, Tyler Rowe, Jacob C. Hauser, Joseph P. Kolb, Kenneth A. Meshaw, Stephanie M. Fogerson, Beth A. Hollister
- 5821 5821 利用靶向肿瘤胞内抗原PRAME的可溶性T细胞受体TCR开发针对PRAME阳性肿瘤的治疗与放射性诊断制剂 Utilize a soluble T-cell receptor TCR targeting tumor intracellular antigen PRAME to develop therapeutic and radioactive diagnostic agents for PRAME-positive tumors Yujun Huang, Xiao Liang, Yajuan Xue
- 5822 5822 通过四嗪连接标记的131I-FAPi二聚体在人胶质母细胞瘤异种移植模型中靶向放射性核素治疗的疗效 Efficacy of targeted radionuclide therapy Using 131 I-FAPi dimers labeled via tetrazine ligation in a human glioblastoma xenograft model Umberto Maria Battisti, Marcel Martin, Vladimir Shalgunov, Filipe Elvas, Alan Miranda, Andreas Jensen, Matthias Herth
- 5824 5824 ATNM-400临床前开发的首次靶点披露：一种在实体瘤中具有泛肿瘤疗效的同类首创锕-225放射性偶联物 First target disclosure for the preclinical development of ATNM-400, a first-in-class actinium-225 radioconjugate with pan-tumor efficacy in solid tumors Amanda S. Chin, Sumit Mukherjee, Jason Li, Karina Peregrina, Debbie Lewis, Le-Cun Xu, Dhiren Patel, Madhuri Vusirikala, Monideepa Roy, Adeela Kamal
-
-
- 5827 5827 Actimab-A（一种CD33靶向的锕-225放射性偶联物）通过转录重编程驱动不依赖突变的抗白血病活性，并与标准疗法在AML中产生协同作用 Actimab-A, a CD33-targeted actinium-225 radioconjugate, drives mutation-agnostic anti-leukemic activity and synergizes with standard therapies in AML through transcriptional reprogramming Amanda S. Chin, Merve Sahin, Jason Li, Le-Cun Xu, Monideepa Roy, Madhuri Vusirikala, Kaitlyn H. Ko, Wenbin Xiao, Adeela Kamal, Sheng F. Cai
